Dialog Box

Loading...

Non Hodgkin Lymphoma Clinical Trials (NSW)

The following are a number of clinical trials that are available in NSW. These trials may also be available at other sites across Australia so please check with your treating doctor about any trials that may be of interest to you.

  • It should also be noted that clinical trials do have excusion criteria and again your doctors is the best person to ask about this.

NHL Clinical Trials: Overview    

 

Lymphoma Type Trial Information Trial Locations Trial Phase  Trial Status

Primary CNS

 Rituximab in Primary CNS Lymphoma

Concord Hospital

Royal Prince Alfred

Westmead Hospital

 N/A

 Active Recruiting 

Diffuse Large B Cell

 Double blind randomized phase III study of Lenalidomide (Revlimid) maintenance versus placebo in responding elderly patients with DLBCL and treated with R-CHOP in first line

 Calvary Mater Newcastle Canberra 

Concord Hospital 

St George/Sutherland Hospital

Phase 3

Active Recruiting 

Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin Lymphoma Grades 1, 2 or 3a

A Randomized, Open-label, Multicenter Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab

Canberra Hospital

N/A

 Active Recruiting

Relapsed or refractory mantle cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia/small lymphocytic lymphoma or diffuse large B-cell lymphoma

A Phase 2 study of SAR245409

Nepean Hospital

 Phase 2

 Active Recruiting

 Previously Untreated, Advanced Stage Follicular Lymphoma

 A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 plus CVP vs. MabThera(R) plus CVP, Followed by GP2013 or MabThera(R) Maintenance Therapy in Patients with Previously Untreated, Advanced Stage Follicular Lymphoma 

  St George/Sutherland Hospital

 Phase 3

Active Recruiting 

  Follicular Lymphoma- refractory

 An Open-label, Multicentre, Single-arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects with Refractory Follicular Lymphoma 

Concord Hospital 

Phase 2 

  Active Recruiting

 Follicular Lymphoma- diagnosed after 1st January 2011

The lymphoma lifestyle, environment and family study (LEAF Study) 

Concord Hospital

Gosford Hospital

Prince of Wales Hospital

St George/Sutherland 

St Vincent’s Hospital

Westmead Hospital

Wollongong Hospital  

N/A 

 Active Recruiting 

  Indolent NHL refractory to rituximab

A randomised, open label, multi-centre, Phase III study to investigate the efficacy of bendamustine compared to treatment of physician’s choice in the treatment of subjects with indolent NHL refractory to rituximab 

Concord Hospital

Gosford Hospital

Lismore Hospital

Royal Prince Alfred Hospital

Tweed Hospital

Westmead Hospital 

 Phase 3 

 Active Recruiting 

 Relapsed or refractory mantle cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia/small lymphocytic lymphoma or diffuse large B-cell lymphoma

A Phase 2 study of SAR245409 in patients with relapsed or refractory mantle cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia/small lymphocytic lymphoma or diffuse large B-cell lymphoma. 

 Nepean Hospital

 Phase 2

 Active Recruiting

 Patients with CD30-Positive Cutaneous T-Cell Lymphoma

 A Randomized Open-Label Phase 3 Trial of brentuximab vedotin (SGN-35) versus Physician's Choice (Methotrexate or Bexarotene)

 Concord Hospital

 Phase 3

 Active Recruiting

 Diffuse Large B-Cell CD20+ lymphoma- responding elderly patients

Double blind randomized phase III study of Lenalidomide (Revlimid) maintenance versus placebo in responding elderly patients with DLBCL and treated with R-CHOP in first line 

 Calvary Mater Newcastle

Canberra Hospital

Concord Hospital

St George/Sutherland Hospital

 Phase 3

Active Recruiting 

 Previously Untreated, Advanced Stage Follicular Lymphoma

A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 plus CVP vs. MabThera(R) plus CVP, Followed by GP2013 or MabThera(R) Maintenance Therapy in Patients with Previously Untreated, Advanced Stage Follicular Lymphoma 

St George/Sutherland Hospital 

 Phase 3

 Active Recruiting

 Mantle Cell Lymphoma- relapsed or refractory

A Randomized Phase 4 study Comparing Intravenous Temsirolimus (TEMSR) Regimens in Subjects with Relapsed, Refractory Mantle Cell Lymphoma 

 St George/Sutherland Hospital

 Phase 4

 Active Recruiting

 Refractory Follicular Lymphoma

An Open-label, Multicentre, Single-arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects with Refractory Follicular Lymphoma 

Concord Hospital 

 Phase 2

Active Recruiting 

 Primary CNS

 Rituximab in Primary CNS Lymphoma

Concord Hospital

Royal Prince Alfred Westmead Hospital 

 N/A

Active Recruiting 

 DLBC

Double blind randomized phase III study of Lenalidomide (Revlimid) maintenance versus placebo in responding elderly patients with DLBCL and treated with R-CHOP in first line 

 Calvary Mater Newcastle Canberra

Concord Hospital 

St George/Sutherland Hospital 

  Phase 3

Active Recruiting

 Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular non-Hodgkin Lymphoma Grades 1, 2 or 3a

A Randomized, Open-label, Multicenter Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab 

Canberra Hospital 

 NA

Active Recruiting 

 Relapsed or refractory mantle cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia/small lymphocytic lymphoma or diffuse large B-cell lymphoma

A Phase 2 study of SAR245409 

Nepean Hospital 

 Phase 2

 Active Recruiting

 NHL- previously untreated- advanced indolent 

 A multi-centre phase III, open-label randomized study in previously untreated patients with advanced indolent non-hodgkin lymphoma evaluating the benefit of GA101 (RO5072759) plus chemotherapy compared with rituximab plus chemotherapy followed by GA101 or rituximab maintenance therapy in responders

 Concord Hospital/Westmead Hospital

 Phase 3

Active Recruiting

 Previously untreated patients with advanced indolent non-Hodgkin lymphoma

 A multi-centre phase III, open-label randomized study in previously untreated patients with advanced indolent non-hodgkin lymphoma evaluating the benefit of GA101 (RO5072759) plus chemotherapy compared with rituximab plus chemotherapy followed by GA101 or rituximab maintenance therapy in responders 

Concord Hospital 

Westmead Hospital 

 Phase 3

 Active Recruiting

 Peripheral T-Cell Lymphoma - relapsed or refactory 

A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator’s Choice (Selected Single Agent) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma 

Concord Hospital

Gosford Hospital 

 Phase 3

 Active Recruiting